• News
  • Medical

Lpath receives US patent for ocular conditions

San Diego-based Lpath Inc. (Nasdaq: LPTN), a developer of bioactive lipid-targeted therapeutics, has received official notification from the U.S. Patent and Trademark Office that it has been issued another key patent supporting its iSONEP program.

The patent, titled "Compositions and Methods for Treating Ocular Conditions," claims methods of using monoclonal antibodies (including iSONEP) that bind sphingosine-1-phosphate (S1P) in the treatment of a wide variety of ocular conditions, including wet age-related macular degeneration (AMD).

Lpath is conducting a Phase 2 clinical trial for iSONEP, the Nexus trial, which is evaluating the anti-S1P antibody's safety and efficacy in wet-AMD patients that have not responded well to existing anti-VEGF therapies including Lucentis, Avastin and Eylea.

Lpath entered into an agreement with Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP.

Additionally, Lpath is independently conducting a Phase 2 trial in renal cell carcinoma patients with ASONEP, an anti-S1P antibody that is formulated for systemic delivery.

Both iSONEP and ASONEP are first-in-class therapeutics developed using Lpath's ImmuneY2 drug-discovery engine. Antibodies developed via this discovery engine are designed to target bioactive signaling lipids, such as S1P, that are involved in cancer, AMD, inflammatory and auto-immune disorders and many other diseases.

User Response
0 UserComments